about
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusibRhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stabilityNew Features about Tau Function and DysfunctionHemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndromeAdditional mechanisms conferring genetic susceptibility to Alzheimer's diseaseManzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseasesGlycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.The need for better AD animal models.Potent beta-amyloid modulators.Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls.The role of extracellular Tau in the spreading of neurofibrillary pathology.Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.Recent developments in tau-based therapeutics for neurodegenerative diseases.Overcoming cell death and tau phosphorylation mediated by PI3K-inhibition: a cell assay to measure neuroprotection.Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.Further understanding of tau phosphorylation: implications for therapy.MicroRNAs in Neurodegenerative Diseases.Recent developments in tau-based therapeutics for Alzheimer's disease and related dementsia.Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment.Presenilin 1 interaction in the brain with a novel member of the Armadillo family.Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells.The role of tau phosphorylation in transfected COS-1 cells.Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture.Neuronal membrane cholesterol loss enhances amyloid peptide generation.Deconstructing GSK-3: The Fine Regulation of Its Activity.Wnt-1 expression in PC12 cells induces exon 15 deletion and expression of L-APP.The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities.NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice.A delta-catenin signaling pathway leading to dendritic protrusions.Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.Toward common mechanisms for risk factors in Alzheimer's syndrome.Strong buffering capacity of insect cells. Implications for the baculovirus expression system.
P50
Q24610904-C08E29D3-43CC-4A32-96C6-2340CB32F41BQ24671491-3F868317-6B26-42AD-9EB6-2BDC54F8809DQ26750922-2B77E4B4-94D0-44D9-B79D-42E11983456BQ28144688-89A8E1AA-E6B8-4E5D-BB78-8DBD66FAA664Q28391511-EC450913-6CAA-4F80-8F25-37870EA2CAA4Q33251948-B30F748C-181E-4287-A27A-7E5A582E6998Q33294648-0B65D245-FF5A-4E05-BD80-D5B3DACAFCD7Q34296827-4D625488-7CBE-4099-9802-48131FE5CCC1Q34398962-C1DEEBA1-1B27-40D7-A692-34D4E504E186Q37103011-9B1A6F0A-5878-4072-BDC4-911CFAD8121CQ37306377-8E436FBC-0CB8-4203-B083-49C5B197CBD0Q37734856-C528BC95-88DB-4E94-A857-B0DA9C88D94DQ37779109-5229F6F4-DC00-4EF0-B271-B9EBF9DFB2CBQ37813731-5FD41011-4517-458B-89E6-390D16985281Q37827537-70E83FB6-9A56-4133-8C99-25223B083E66Q37946881-2B5D65A2-28D2-4765-8974-D4BDAA93C5A9Q37978196-23B9A310-E0E6-499A-B020-DD12DAFCFBA0Q38101982-6FDC2754-F2F6-4FF1-82DF-3A4808690020Q38149943-D1FD0FF6-F5DA-4F9D-9B24-37F34FFAB760Q38181831-55ABAFDC-0ABB-4DEC-B8A4-16A12BA2C330Q38306065-D3D4A7E6-562D-4707-91D7-60E9F6F9D615Q38609658-90B79B9B-7083-4922-8157-2FAD7F743444Q39111437-E8F7F07B-BF6B-4B44-838E-0E01A3995446Q40352789-E4A59084-F5BF-4D7F-BFF7-E7EC2059EC7DQ40380514-AF2C0CA0-9F66-48E5-8393-62DEED385038Q40429251-2552338E-6069-496B-9EFC-406892708A6CQ40809749-5C0CF070-ACF2-436D-A21E-1FB2EBE37A98Q41116079-E99B0138-ABD4-4923-B362-8DE9455A3430Q41197954-22E085D6-BC48-40D4-B417-939A12241237Q41327023-3C28AFA7-80B7-4B31-A1AC-CE4202884B56Q41596913-DB7271E8-EF4D-45C1-87F6-D66A1A09F496Q41967267-72D5A51B-AC6F-49FF-AB17-133B48493302Q42135408-67DC3E01-4B45-42E5-8D56-5103D42A656AQ44944491-491A28C7-977F-419A-ADF7-70085DBCBADEQ45775389-DEF264EA-032D-4C7B-90EE-348B92CE0ABAQ46197592-9E90D2CE-A5AA-47BB-9BA6-9A24E9A2AA3EQ46352528-F7711B96-374D-4CFC-B997-7C0BA742B6F1Q46519468-CD3898C3-11FD-4E52-9D83-5E2A5EF032EAQ47097900-202DD2DA-F4AC-40AD-A23C-9229D89CFF13Q47743999-81421E0F-61F5-46D2-B842-92AC31DFDBC7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miguel Medina
@ast
Miguel Medina
@en
Miguel Medina
@es
Miguel Medina
@nl
Miguel Medina
@sl
type
label
Miguel Medina
@ast
Miguel Medina
@en
Miguel Medina
@es
Miguel Medina
@nl
Miguel Medina
@sl
prefLabel
Miguel Medina
@ast
Miguel Medina
@en
Miguel Medina
@es
Miguel Medina
@nl
Miguel Medina
@sl
P1153
P1053
H-5676-2012
P106
P1153
55559087700
55701313600
57189580915
P21
P2798
P31
P3829
P3835
miguel-medina15
P496
0000-0002-7016-5340